Physician profile
Maen Hussein
NPI 1356332506
$172,052.74
in general payments reported to CMS, 2019-2025
100 companies · $35K in 2025
The $35K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $18K · 2021: $15K · 2022: $14K · 2023: $38K · 2024: $28K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $66K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $13K · Honoraria: $2,768 · Travel and Lodging: $1,406 · Long Term Medical Supply Or Device Loan: $665 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,520.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,135.78 |
| Food and Beverage | $13,075.87 |
| Honoraria | $2,767.50 |
| Travel and Lodging | $1,405.50 |
| Long Term Medical Supply Or Device Loan | $665.16 |
| Education | $130.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24,087.51 | 2019-2025 | Rybrevant, Erleada, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $19,343.79 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Ipsen Biopharmaceuticals, INC | $14,231.63 | 2019-2024 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals LP | $13,048.95 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Pfizer INC. | $10,345.94 | 2019-2025 | |
| Boehringer Ingelheim International Gmbh | $8,148.79 | 2021-2022 | |
| F. Hoffmann-La Roche Ag | $7,988.04 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,035.88 | 2019-2025 | |
| Abbvie INC. | $4,737.47 | 2020-2025 | |
| Lilly USA, LLC | $3,987.47 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Morphosys, US INC. | $3,841.12 | 2021-2024 | Monjuvi |
| Genzyme Corporation | $3,747.14 | 2019-2025 | |
| Daiichi Sankyo INC. | $3,591.31 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Stemline Therapeutics INC. | $3,303.63 | 2023-2025 | Orserdu, Elzonris |
| Karyopharm Therapeutics INC. | $3,126.42 | 2020-2024 | Xpovio |
Show all 95 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,984.52 | 2020-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $2,917.86 | 2023-2025 | Besremi |
| Incyte Corporation | $2,756.00 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Genentech USA, INC. | $2,613.16 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Janssen Scientific Affairs, LLC | $2,532.50 | 2023 | Imbruvica, Rybrevant |
| Athenex Pharmaceutical Division, LLC | $2,420.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $2,264.27 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $1,983.34 | 2019-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $1,884.46 | 2022-2025 | Fotivda |
| Azurity Pharmaceuticals, INC. | $1,875.00 | 2024 | Vivimusta |
| Exelixis INC. | $1,611.14 | 2023-2025 | Cabometyx |
| Celgene Corporation | $1,396.24 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Beone Medicines USA, INC. | $1,284.06 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $1,259.08 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $1,173.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Cti Biopharma Corp. | $1,159.91 | 2022-2023 | Vonjo |
| Amgen INC. | $808.75 | 2019-2025 | Blincyto, Nplate, Xgeva |
| Eli Lilly and Company | $800.00 | 2021-2023 | |
| Eisai INC. | $743.11 | 2019-2025 | |
| Seagen INC. | $657.71 | 2019-2023 | Adcetris, Tukysa, Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $645.54 | 2019-2023 | Imbruvica |
| Gilead Sciences, INC. | $632.39 | 2021-2025 | Trodelvy |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $511.28 | 2020 | |
| Adc Therapeutics America, INC. | $439.84 | 2022-2025 | |
| Kite Pharma, INC. | $422.45 | 2021-2025 | Yescarta |
| Astellas Pharma US INC | $388.71 | 2020-2025 | Vyloy, Padcev, Cresemba |
| Glaxosmithkline, LLC. | $363.90 | 2020-2025 | Jemperli, Ojjaara |
| Octapharma USA, INC. | $331.60 | 2020 | |
| Blueprint Medicines Corporation | $315.27 | 2020-2024 | Ayvakit |
| Cvrx, INC. | $288.12 | 2024-2025 | Barostim Neo System |
| Rigel Pharmaceuticals, INC. | $267.61 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Emd Serono, INC. | $258.13 | 2019-2025 | |
| Array Biopharma INC | $256.21 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $232.05 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $225.08 | 2019-2025 | Fruzaqla, Alunbrig |
| Foundation Medicine, INC. | $211.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.81 | 2019-2025 | |
| Genmab U.S., INC. | $157.36 | 2023-2025 | Epkinly |
| Sobi, INC | $134.80 | 2024 | |
| Agios Pharmaceuticals, INC. | $134.29 | 2019-2024 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $125.81 | 2019-2024 | Ultomiris |
| Clovis Oncology, INC. | $120.99 | 2019 | |
| Intuitive Surgical, INC. | $115.17 | 2022 | |
| Heron Therapeutics, INC. | $107.30 | 2019-2022 | |
| Taiho Oncology, INC. | $90.94 | 2019-2025 | |
| G1 Therapeutics, INC. | $86.75 | 2022-2023 | Cosela |
| Amag Pharmaceuticals, INC. | $86.01 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $82.03 | 2025 | |
| Sun Pharmaceutical Industries INC. | $80.65 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $76.70 | 2023-2024 | Monoferric |
| Global Blood Therapeutics, INC. | $71.16 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $68.85 | 2022 | |
| Dendreon Pharmaceuticals LLC | $67.94 | 2019-2025 | Provenge |
| Aurobindo Pharma USA, INC. | $65.95 | 2019-2020 | |
| Tersera Therapeutics LLC | $62.16 | 2021-2023 | Quzyttir |
| Kyowa Kirin, INC. | $56.73 | 2019-2020 | |
| Puma Biotechnology, INC. | $55.82 | 2020-2025 | |
| Dova Pharmaceuticals | $55.65 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $51.49 | 2019-2020 | |
| Verastem, INC. | $42.56 | 2019 | |
| Tesaro, INC. | $40.05 | 2019 | |
| Secura Bio, INC. | $38.47 | 2019-2022 | |
| Csl Behring | $33.52 | 2021-2024 | Idelvion, Afstyla |
| Mirati Therapeutics, INC. | $30.48 | 2023-2024 | Krazati |
| Legend Biotech USA INC. | $28.99 | 2025 | Carvykti |
| Immunogen, INC. | $27.82 | 2023 | Elahere |
| Telix Pharmaceuticals | $22.93 | 2023 | Illuccix |
| Iovance Biotherapeutics, INC. | $22.45 | 2025 | Amtagvi |
| Geron Corporation | $22.41 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $20.14 | 2023 | |
| Tg Therapeutics, INC. | $18.54 | 2022 | |
| Syndax Pharmaceuticals, INC. | $17.29 | 2025 | |
| Tempus Ai, INC | $16.77 | 2024 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $15.90 | 2024 | Qinlock |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Ge Healthcare | $11.79 | 2021 | |
| Sirtex Medical INC | $11.63 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.59 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $11.22 | 2019 | |
| Veracyte, INC. | $1.23 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,052.34 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maen Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.